CRNX Overview
Upcoming Projects (CRNX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CRNX)
-
Investigating the emerging therapies for treating acromegaly.
Tickers: CRNX, AMYT
Executed On: Feb 21, 2024 at 03:00 PM EST -
Discussing paltusotine from Crinetics and the PATHFNDR-1 and 2 trials in acromegaly.
Ticker: CRNX
Executed On: Aug 08, 2023 at 06:00 PM EDT -
Discussing the development landscape of treatments for Congenital Hyperinsulinism (CHI) specifically: CRN04777, RZ358, and Avexitide.
Tickers: CRNX, RZLT, EIGR
Executed On: Feb 22, 2022 at 11:00 AM EST
Expired Projects (CRNX)
-
After its recent IPO we look at Crinetics’ lead pipeline candidate, CRN00808, in treating Acromegaly
Tickers: CRNX, NVS, IPN.PA
Execute By: Nov 07, 2018
Upcoming & Overdue Catalysts (CRNX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (CRNX)
-
Crinetics Pharmaceuticals (CRNX) Announces Phase 2 ACROBAT Edge Study Results with Paltusotine in Acromegaly
Ticker: CRNX
Occurred on: Oct 26, 2020 -
Crinetics (CRNX) Expects to Initiate Phase 1 of CRN02481 For the Treatment of Hyperinsulinemia in 1H 2019
Ticker: CRNX
Occurred on: May 21, 2019 -
Crinetics (CRNX) Expecting to Initiate Phase 2 of CRN00808 For the Treatment of Acromegaly in early 2019
Ticker: CRNX
Occurred on: Dec 28, 2018
Strategic Initiatives (CRNX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
